ProsTAV^®

Blood-based biomarker that quantifies telomere biology to support earlier precise urology decisions

Designed for decision-making and reducing unnecessary biopsies.

Prostate health & cancer

+1,400,000

Men diagnosed with prostate cancer worldwide

+375,300

Deaths from the disease worldwide

1 in 8 men

Will be affected during their lifetime

The 2nd

Most common cancer worldwide is prostate

What is ProsTAV^®?

Measured under CLIA/ISO 15189 quality standards.

ProsTAV^® combines selected clinical variables with telomere variables measured using Life Length’s patented HT-Q-FISH (TAT®) technology.

The result is a clinically interpretable risk assessment that supports urologists in the diagnosis of prostate cancer, and complements existing tools

Sample type

Whole blood, EDTA

Shipping kit

Kit provided with instructions for healthcare professionals

What does it measure?

ProsTAV® Score

Interpretable risk index that links the telomere profile (TAT®) with the probability of clinically significant prostate cancer (csPCa) in men with PSA 3–10 ng/mL.

Probability of Gleason ≥7 (csPCa)

Individualized likelihood of finding tumors with Gleason ≥7.

Probability of Gleason ≥8

Individualized likelihood of higher-aggressiveness disease

Biopsy decision support

Pre-biopsy triage to help the urologist determine the need for confirmatory biopsy, especially in patients with ProsTAV® Score >10%.

Who is it for?

Why telomere-based risk matters in urology

ProsTAV^® is a blood-based, telomere-biology biomarker that uses Life Length’s TAT® (HT-Q-FISH) to convert single-cell telomere metrics into a clinically interpretable risk band that complements PSA and MRI, supporting pre-biopsy decision-making. Evidence from clinical studies shows ProsTAV® helps identify men at risk of clinically significant disease.

Intended use in pre-biopsy triage in men with PSA 3–10 ng/mL when the biopsy decision is equivocal, with the goal of reducing unnecessary biopsies.

PSA 3–10 ng/mL

Refine risk and clarify biopsy need

Uncertain biopsy decision

Support clinical decision in borderline cases

Pre-biopsy triage

Help reduce unnecessary procedures

Blood-based test

Objective readout from a blood draw

Clinical support

Supporting urologists in areas of uncertainty.

Avoiding unnecessary biopsies

Among men with elevated PSA, ProsTAV^® helps avoid biopsy in those unlikely to benefit (score <10), complementing MRI and clinical judgment.

Complementary to MRI

In men with PSA 3–10 ng/mL and an equivocal biopsy decision, ProsTAV^® provides a blood-based, objective readout that supports pre-biopsy decision-making and helps reduce unnecessary biopsies.

Clinical performance (observational cohort, n=1,043; threshold = 0.10)

Output: probability of clinically significant prostate cancer (csPCa). Metrics for biopsy decision support.

Endpoint	Sensitivity	Specificity	PPV	NPV	Saved biopsies
Gleason ≥7	90%	33%	29%	91%	33%
Gleason ≥8	100%	33%	9%	100%	33%

Actionable results

Better prostate cancer decisions

The ProsTAV^® report places patients into clearly defined prostate-cancer risk bands by integrating single-cell telomere metrics (TAT®) into a clinically actionable format that complements PSA and MRI findings. Results can be shown as categorical risk levels (Low, Intermediate, High) and benchmarked against validated patient cohorts.

ProsTAV^® transforms complex telomere distributions into an easy-to-read clinical report.

Not detected by MRI result

ProsTAV^® identifies as biopsy candidates (ProsTAV® score > 10)

PI-RADS 1

PI-RADS 2

PI-RADS 3

Total

MRI misses some csPCa (PI-RADS 1–3). ProsTAV^® flags them. In biopsy-confirmed cases that MRI didn’t qualify for biopsy (low PI-RADS), ProsTAV® score >10 correctly identified 21 of 24 patients (see Table 1).

ProsTAV^® accurately spares biopsies in men who don’t need them (score <10). It correctly reclassified many cases with PI-RADS ≥3 that MRI alone would have sent to biopsy, despite the absence of clinically significant prostate cancer—avoiding unnecessary procedures.

Frequently Asked Questions

Who are the candidates for the test?

Men, older than 40 years, with PSA (prostate specific antigen) levels between 3 and 9,99 ng/ml.

How is the test performed?

A single EDTA whole-blood draw (~8 mL).

When will I receive the result?

Typically 7–10 business days after the sample arrives at the laboratory (may vary by market/regulatory route).

What are the info references?

Cáncer de Próstata – SEOM: Sociedad Española de Oncología Médica. (n.d.)., from Casos nuevos por año son diagnosticados en España.

Sung, H., et al. (2021). Global CancerStatistics 2020: https://doi.org/10.3322/CAAC.21660

Xu, J., et al. (2020). Leukocyte telomere length is associated with aggressive prostate cancer in localized prostate cancer patients. EBioMedicine, 52. https://doi.org/10.1016/J.EBIOM.2019.102616

Contraindications and Patient Exclusions

·    If the person is undergoing an acute infectious process at the time the sample is taken, the lymphocytes could be altered. It is recommended to wait one month.
·    Severe active liver, lung or kidney disease.
·    If the person has received treatment with alpha-5-reductase inhibitors.
·    If the person has active neoplasia diagnosed in the last 5 years.
·    ProsTAV has only been validated, for the moment, for the white/Caucasian race. Due to genetic differences, its use in other races is not recommended.

Got any questions?

Contact our team of experts

Full Name

Country of residence

Are you a medical professional?

Are you contacting us on behalf of a company?

If yes, please enter company name

Message

ProsTAV®